206 related articles for article (PubMed ID: 26460823)
1. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.
Ahn S; Ahn S; Van Vrancken M; Lee M; Ha SY; Lee H; Min BH; Lee JH; Kim JJ; Choi S; Jung SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kim KM
Oncotarget; 2015 Nov; 6(35):38372-80. PubMed ID: 26460823
[TBL] [Abstract][Full Text] [Related]
2. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer.
Xu C; Liu Y; Ge X; Jiang D; Zhang Y; Ji Y; Hou J; Huang J; Su J; Zeng H; Qin J; Hou Y
Diagn Pathol; 2017 May; 12(1):41. PubMed ID: 28549444
[TBL] [Abstract][Full Text] [Related]
3. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance.
Huang SC; Ng KF; Lee SE; Chen KH; Yeh TS; Chen TC
Gastric Cancer; 2016 Jan; 19(1):176-82. PubMed ID: 25512144
[TBL] [Abstract][Full Text] [Related]
4. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer.
Tominaga N; Gotoda T; Hara M; Hale MD; Tsuchiya T; Matsubayashi J; Kono S; Kusano C; Itoi T; Fujimoto K; Moriyasu F; Grabsch HI
Gastric Cancer; 2016 Apr; 19(2):553-560. PubMed ID: 25987463
[TBL] [Abstract][Full Text] [Related]
5. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
[TBL] [Abstract][Full Text] [Related]
6. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
[TBL] [Abstract][Full Text] [Related]
7. Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma.
Nergiz D; Alikanoğlu AS; Süren D; Gömceli İ; Öztürk B
Indian J Pathol Microbiol; 2022; 65(2):321-327. PubMed ID: 35435366
[TBL] [Abstract][Full Text] [Related]
8. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.
Lee S; de Boer WB; Fermoyle S; Platten M; Kumarasinghe MP
Histopathology; 2011 Nov; 59(5):832-40. PubMed ID: 22092394
[TBL] [Abstract][Full Text] [Related]
9. Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma.
Kimura M; Tsuda H; Morita D; Shinto E; Tanimoto T; Ichikura T; Mochizuki H; Matsubara O
Jpn J Clin Oncol; 2005 Jun; 35(6):324-31. PubMed ID: 15928192
[TBL] [Abstract][Full Text] [Related]
10. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
Fazlollahi L; Remotti HE; Iuga A; Yang HM; Lagana SM; Sepulveda AR
Arch Pathol Lab Med; 2018 Apr; 142(4):516-522. PubMed ID: 28782986
[TBL] [Abstract][Full Text] [Related]
11. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
[TBL] [Abstract][Full Text] [Related]
12. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
[TBL] [Abstract][Full Text] [Related]
13. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens.
Yang J; Luo H; Li Y; Li J; Cai Z; Su X; Dai D; Du W; Chen T; Chen M
Cell Biochem Biophys; 2012 Jan; 62(1):221-8. PubMed ID: 21927816
[TBL] [Abstract][Full Text] [Related]
15. Are biopsy specimens predictive of HER2 status in gastric cancer patients?
Pirrelli M; Caruso ML; Di Maggio M; Armentano R; Valentini AM
Dig Dis Sci; 2013 Feb; 58(2):397-404. PubMed ID: 22918687
[TBL] [Abstract][Full Text] [Related]
16. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
Park SR; Park YS; Ryu MH; Ryoo BY; Woo CG; Jung HY; Lee JH; Lee GH; Kang YK
Eur J Cancer; 2016 Jan; 53():42-50. PubMed ID: 26693898
[TBL] [Abstract][Full Text] [Related]
17. Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity.
Rottmann D; Assem H; Matsumoto N; Wong S; Hui P; Buza N
Int J Gynecol Pathol; 2021 May; 40(3):263-271. PubMed ID: 32897955
[TBL] [Abstract][Full Text] [Related]
18. HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program.
Kumarasinghe MP; Morey A; Bilous M; Farshid G; Francis G; Lampe G; McCue G; Von Neumann-Cosel V; Fox SB
Pathology; 2017 Oct; 49(6):575-581. PubMed ID: 28823752
[TBL] [Abstract][Full Text] [Related]
19. Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing: A Direct Comparison Study with Immunohistochemistry.
Choi S; Chu J; Kim B; Ha SY; Kim ST; Lee J; Kang WK; Han H; Sohn I; Kim KM
J Mol Diagn; 2019 Jul; 21(4):612-622. PubMed ID: 31022472
[TBL] [Abstract][Full Text] [Related]
20. HER2 expression variability between primary gastric cancers and corresponding lymph node metastases.
Qiu Z; Sun W; Zhou C; Zhang J
Hepatogastroenterology; 2015; 62(137):231-3. PubMed ID: 25911901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
